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Abstract 30 
Female renal transplant recipients of childbearing age may ask what the 31 
outcomes are for pregnancy and whether pregnancy will affect graft function. 32 
We analysed obstetric and transplant outcomes among renal transplant 33 
recipients in our centre who have been pregnant between 1973 and 2013. A 34 
case-cohort study was performed identifying 83 pairs of pregnant and non-35 
pregnant controls matched for sex, age, transplant vintage and creatinine. 36 
There were 138 pregnancies reported from 89 renal transplant recipients. 37 
There were live births in 74% of pregnancies with high prevalence of 38 
prematurity (61%), low birth weight (52%) and preeclampsia (14%). Lower 39 
eGFR (OR 0.98; p=0.05) and higher uPCR (OR 1.86; p=0.02) at conception 40 
were independent predictors for poor composite obstetric outcome. Lower 41 
eGFR (OR 0.98; p=0.04), higher uPCR (OR 1.50; p=0.04) and live organ 42 
donation (OR 0.35; p=0.02) were predictors of ≥20% loss of eGFR between 43 
immediately pre-pregnancy and 1 year after delivery. There was no difference 44 
in eGFR at 1, 5 and 10 years in pregnant women compared with non-45 
pregnant controls and a pregnancy was not associated with poorer 10-year 46 
transplant or 20-year patient survival. Despite high rates of obstetric 47 
complications, most women had successful pregnancies with good long-term 48 
transplant function. 49 
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Introduction 74 
Fertility is restored within a few months following kidney transplantation. 75 
Approximately 2% of female kidney transplant recipients of childbearing age 76 
become pregnant(1). Published data on pregnancy outcomes after kidney 77 
transplantation derive from self-reporting registries and single-centre 78 
studies(2-6). Transplant function(3, 5, 7), pre-existing hypertension(5), and 79 
time since transplantation(2, 7, 8) may predict risk to the mother, kidney and 80 
fetus. Data on transplant and maternal survival suggest that live birth does not 81 
adversely affect patient or allograft survival(4) but these are limited by patient 82 
overlap (in registries), classification differences, reporting biases or single-83 
centre studies with short follow-up and no adequate control group. 84 
This study aimed to examine obstetric and kidney outcomes in women with 85 
kidney transplants, investigate changes in outcomes over four decades and 86 
explore factors influencing obstetric and kidney outcomes. We compared 87 
maternal and transplant outcomes in pregnancy to matched patients, who did 88 
not become pregnant over this period. 89 
 90 
Patients and Methods 91 
Study population and baseline data 92 
This was a single-centre retrospective cohort study from Glasgow Transplant 93 
Unit, where almost 3000 adult renal transplants have been performed 94 
between 1970 and 2014 with a prevalent transplant population of 95 
approximately 900 adults at December 2014. 96 
All women reporting a pregnancy between January 1st, 1973 and February 97 
28th, 2013 whilst having a functioning kidney transplant were identified from 98 
 5 
the electronic patient record. Those requiring temporary dialysis during 99 
pregnancy or returning to long-term dialysis shortly before delivery were 100 
included. All women delivered at three different obstetric units across the 101 
region. Two investigators (SS, MG) extracted the information needed 102 
independently using a data collection form. 103 
The following characteristics were recorded: age, ethnicity, weight, previous 104 
pregnancies, last menstrual period, delivery date, clinic blood pressure (BP), 105 
cause of established renal failure (ERF), time on renal replacement therapy 106 
(RRT), prior kidney transplant, decade of transplantation, time since 107 
transplant, transplant source (deceased or live donation), prior acute rejection, 108 
pre- and post-pregnancy serum creatinine and urinary protein quantification. 109 
Maintenance immunosuppression regimen used prior to and during 110 
pregnancy was recorded.  111 
Outcome data were gestational age, birth weight, pregnancy outcome, 112 
obstetric complications (gestational hypertension, preeclampsia and 113 
caesarean section), neonatal survival (>28 days), and presence of congenital 114 
anomaly. Transplant outcomes were acute rejection during pregnancy, 115 
transplant loss during pregnancy and within two years post-partum, and 116 
deterioration of renal function associated with pregnancy. Patient and 117 
transplant outcomes were analysed from time of delivery. 118 
We analysed obstetric outcomes in two subgroups of patients according to 119 
estimated glomerular filtration rate (eGFR) (≤ or >45ml/min/1.73m2) assuming 120 
that women with normal or mildly impaired renal function have better 121 
outcomes. The cut-off was selected as being consistent with the KDIGO 122 
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classification of Stage 3a and 3b chronic kidney disease (CKD) and was felt to 123 
be clinically meaningful. 124 
Estimated glomerular filtration rate was calculated using the Modification of 125 
Diet in Renal Disease formula(9). Urine protein:creatinine ratio (uPCR) was 126 
used as an estimation of proteinuria. If no uPCR value was available, 24-hour 127 
urine protein excretion was used, dividing the value in mg by 10 to achieve 128 
equivalent in mg/mmol(10). Small for gestational age was calculated from 129 
birth weight compared to UK references(11). 130 
 131 
Outcome definitions 132 
Pregnancy outcomes were live birth, miscarriage (<20 weeks gestation), 133 
termination, ectopic pregnancy and stillbirth (≥20 weeks gestation)(12). 134 
Gestational hypertension was defined as new onset hypertension 135 
(BP>140/90mmHg) after 20 weeks gestation without proteinuria in a 136 
previously normotensive woman. Preeclampsia was defined as gestational 137 
hypertension with proteinuria. 138 
Due to low event rates in each individual adverse obstetric outcome, we 139 
defined a composite adverse obstetric outcome incorporating reported first or 140 
second trimester losses, stillbirths, neonatal mortality (death in first 28 days of 141 
life), very preterm births (<32 weeks gestation) and fetal congenital 142 
anomalies. Pregnancy associated transplant dysfunction was defined as 143 
≥20% loss of eGFR between results immediately pre-pregnancy and 1 year 144 
after delivery. This threshold has been used by previous studies(3) as a 20% 145 
fall in eGFR reflects a clinically important change in renal function for an 146 
individual patient. The clinical and research activities reported are consistent 147 
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with the Principles of the Declaration of Istanbul as outlined in the ‘Declaration 148 
of Istanbul on Organ Trafficking and Transplant Tourism’.  149 
 150 
Case-cohort study 151 
Long-term transplant and maternal survival rates were compared to a control 152 
cohort of non-pregnant renal transplant recipients using matched survival 153 
analyses. The electronic patient record, case notes and clinic letters were 154 
viewed to ensure that the non-pregnant controls did not become pregnant 155 
over the study period. Non-pregnant women receiving a kidney transplant 156 
matched for age (±5 years), transplant vintage (±10 years) and serum 157 
creatinine (±30mmol/L or 0.34mg/dL) were chosen as controls whilst blinded 158 
for outcomes. To match the age of the graft at conception for non-pregnant 159 
women, transplantation to pregnancy interval was calculated for each 160 
pregnant woman to define a ‘matching day’ and to assign a ‘pre-pregnancy 161 
eGFR’ in each control. For comparisons between groups, the ‘matching day’ 162 
in controls and the last menstrual period day in pregnant renal allograft 163 
recipients were used. Once the match was made, pregnancy to delivery 164 
interval was used to define a ‘simulated delivery day’ and to calculate 165 
‘gestational period’ in control subjects. Serum creatinine was retrieved at 1, 5 166 
and 10 years after ‘delivery day’. Follow-up was censored on date of 167 
transplant failure, death, loss to follow-up or last entry in the electronic patient 168 
record, whichever was first. For women with multiple pregnancies, first 169 
pregnancy post-transplant was matched. Each non-pregnant control was 170 
selected only once. 171 
 172 
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Statistical analyses 173 
Categorical variables were reported as frequencies and percentages, with 174 
mean and standard deviation or medians and interquartile ranges (for skewed 175 
data) reported for continuous variables. Categorical data were compared by 176 
chi-squared test, Fisher’s exact test or logistic regression. Continuous data 177 
were compared by Student’s t-test or linear regression. The Mann-Whitney U 178 
test was used for comparisons of differences in medians. 179 
Univariate binomial logistic regression models were used to assess prognostic 180 
factors for composite adverse obstetric outcome and pregnancy associated 181 
transplant dysfunction. Variables tested were maternal age at pregnancy, time 182 
since transplant, cause of ERF, pre-pregnancy eGFR and proteinuria, decade 183 
of transplant, transplant source, calcineurin inhibitor (CNI) use at time of 184 
pregnancy, presence of hypertension, time on RRT, prior kidney transplant 185 
and prior rejection. Statistically significant factors were tested in separate 186 
multivariable logistic regression models with composite adverse obstetric 187 
outcome and pregnancy associated transplant dysfunction as dependent 188 
variables. 189 
In the case-cohort study mean eGFR at 1, 5 and 10 years were compared by 190 
t-test. Patient survival, overall transplant survival and transplant survival 191 
censored for patient death were plotted using Kaplan–Meier estimates and 192 
compared using log-rank test. 193 
Analyses were performed using SPSS (version 21.0, SPSS Inc.). In all 194 
analyses, p-value <0.05 was considered statistically significant. 195 
 196 
 197 
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Results 198 
There were 138 pregnancies to 89 transplant recipients reported between 199 
1973 and 2013. Median duration of follow-up from first pregnancy was 8.2 200 
years (IQR: 3.8, 16.9). Fifty-seven women had one pregnancy (64.0%), 22 201 
had two pregnancies (24.7%), 7 had three pregnancies (7.9%) and 3 had four 202 
pregnancies (3.4%). Four women had pregnancies with two different kidney 203 
transplants. There was one triplet pregnancy. 204 
One patient required temporary dialysis during pregnancy. Three women 205 
conceived with a functioning transplant for most of their pregnancy but 206 
returned to dialysis before delivery. Median time between transplantation and 207 
pregnancy was 3.6 (IQR: 1.9, 7) years. Median RRT time pre-pregnancy was 208 
6.9 (IQR: 3.8, 10.4) years (Table 1).  209 
 210 
Maternal demographics 211 
Mean ages at time of transplantation and pregnancy were 25.2 (SD 6.4) and 212 
30.3 (SD 5.1) years respectively. The most common primary kidney disease 213 
was reflux nephropathy (48.3%), followed by glomerulonephritis (36.0%), 214 
cystic disease (2.2%), diabetes (1.1%) and other/unknown (12.4%). 215 
Approximately two-thirds of transplanted kidneys were from deceased donors 216 
and 30 (21.7%) women had one previous kidney transplant. Mean systolic 217 
and diastolic BP at conception was 126.9 (SD 16.6) and 80.5 (SD 9.8) mmHg. 218 
Fifty-six (40.6%) women were on antihypertensive therapy before pregnancy. 219 
Six women (4.3%) had an episode of acute rejection of the current transplant 220 
before pregnancy (Table 1). 221 
 222 
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Immunosuppression 223 
Six immunosuppression regimens (all steroid based) were used. The most 224 
common combinations are shown in Figure 1. In the 1970’s, 13 women 225 
(86.7%) were on prednisolone and azathioprine and in the 1980’s 226 
prednisolone with either azathioprine (44.2%) or cyclosporine (42.3%) were 227 
used equally. In the 1990’s, 44 women (89.8%) received CNI-based regimens 228 
and during the last decade, tacrolimus was used more commonly than 229 
cyclosporine (17 vs. 3 women). Four women were taking mycophenolate 230 
mofetil (MMF) at conception despite routine advice issued to all women at our 231 
centre not to become pregnant on MMF. 232 
 233 
Pregnancy outcomes 234 
In the 138 pregnancies, there were 102 (73.9%) live births, 23 (16.7%) 235 
miscarriages, 8 (5.8%) terminations, 3 (2.2%) ectopic pregnancies and 2 236 
(1.4%) stillbirths. There were 16 pregnancies during the first post-transplant 237 
year, resulting in 9 (56.2%) live births, 4 (25.0%) miscarriages and 3 (18.8%) 238 
terminations.  239 
Two women underwent in vitro fertilisation resulting in early miscarriage and 240 
stillbirth.  241 
 242 
Gestational age and mode of delivery 243 
Median gestational age at delivery was 34.3 (IQR: 23.8, 37.4) weeks. Of 102 244 
live births, 62 (60.8%) were preterm (<37 weeks). 5.9% of babies were born at 245 
<32 weeks gestation.  246 
 11 
Of the 102 live births, 22 (21.6%) were vaginal deliveries and 80 (78.4%) were 247 
caesarean deliveries (43 elective, 32 emergency and 5 unknown). Seven 248 
(11.3%) preterm births were vaginal deliveries and the remaining 55 (88.7%) 249 
were caesarean deliveries (28 elective, 24 emergency and 3 unknown).  250 
 251 
Birth weight 252 
Six birth weights were missing. Mean birth weight of all newborns was 2464 253 
(SD 727) g. Forty-one (45.1%) had low birth weight (<2500g), and 6 (6.6%) 254 
had very low birth weight (<1500g). 255 
Of 96 singleton pregnancies with gestational age and birth weight data, 13 256 
(13.5%) and 9 (9.4%) had birth weights below the 10th and 3rd centile for 257 
gestational age respectively. 258 
 259 
Preeclampsia 260 
Data to identify preeclampsia were missing for 8 pregnancies. Preeclampsia 261 
occurred in 15 (14.2%) pregnancies and gestational hypertension occurred in 262 
8 (7.5%).  263 
Median gestational age of babies born to women developing preeclampsia 264 
was less than women who did not [34.1 (IQR: 32.7, 36.0) vs. 36.4 (IQR: 33.8, 265 
38.0) weeks; p=0.005] with lower mean birth weights [2016 (SD 1060) g vs. 266 
2418 (SD 823) g; p=0.12]. Of 11 infants born prematurely due to preeclampsia 267 
with gestational age and birth weight data, only 2 (18.2%) had birth weights 268 
below the 10th centile for gestational age. 269 
Obstetric outcomes according to eGFR subgroups (≤ or >45ml/min/1.73m2) 270 
are shown in Table 2. 271 
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 272 
Neonatal Outcomes 273 
Three (2.9%) congenital abnormalities were reported - one atrial septal defect 274 
and two babies had vesicoureteral reflux. None of these occurred in women 275 
taking MMF at conception. Neonatal death (in first 28 days of life) occurred in 276 
two (2.0%) separate pregnancies. 277 
 278 
Successive pregnancies 279 
Thirty-two women had more than one pregnancy post-transplant. Of 45 280 
subsequent pregnancies, 34 (75.6%) had gestation >20 weeks. Seventeen 281 
(37.8%) reached term, 16 (35.5%) were preterm while 12 (26.7%) ended with 282 
early losses. Rates of live and preterm births, gestational age and birth weight 283 
during subsequent pregnancies were not significantly different compared with 284 
first pregnancies (p=1.00, p=0.28, p=0.88 and p=0.51, respectively). 285 
 286 
Transplant survival and function 287 
Sixteen patients lost their transplant, 3 during pregnancy and a further 13 288 
women within 2 years following delivery. Six women had biopsy-proven acute 289 
rejection (BPAR) during pregnancy from which 2 lost their transplant. All 290 
rejection episodes were treated with high dose oral or intravenous steroids 291 
and a dose increase in the calcineurin inhibitor (or switch from cyclosporine to 292 
tacrolimus). In 3 patients, tacrolimus or cyclosporine levels were deemed 293 
subtherapeutic the period before the rejection episodes.  294 
Pregnancy associated transplant dysfunction occurred in 38 (27.5%) 295 
pregnancies including the women who returned to dialysis. Pre-pregnancy 296 
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serum creatinine was available for 132 pregnancies. Mean eGFR fell from 297 
55.0ml/min/1.73m2 (SD 20.4) to 27.9ml/min/1.73m2 (SD 25.9, n=99) over 10 298 
years in pregnant women. There was no significant difference in pre-299 
pregnancy mean eGFR over the 4 decades examined (p=0.41). Pre-300 
pregnancy proteinuria was available for 125 pregnancies. Median pre-301 
pregnancy uPCR was 15mg/mmol (IQR: 10, 33) compared with 26mg/mmol 302 
(IQR: 10, 43, n=55) at 10 years.  303 
Deceased kidney donation was associated with a larger drop between pre-304 
pregnancy and post-partum eGFR (from 50ml/min/1.73m2 to 42) as compared 305 
with live donation (from 62ml/min/1.73m2 to 60) at 1 year. When we compared 306 
women with single to women with multiple pregnancies, there was no 307 
difference in 10-year eGFR (p=0.68) and transplant survival (p=1.00). 308 
 309 
Univariate and multivariable analysis 310 
Approximately one-third of the cohort (34.1%) had a poor pregnancy outcome, 311 
defined as at least one of first or second trimester loss, stillbirth, neonatal 312 
mortality, very preterm birth and congenital anomaly. Univariate analysis for 313 
the composite adverse obstetric outcome demonstrated reduced eGFR (OR 314 
0.98 per mL/min/1.73m2; 95% CI, 0.96 to 1.00; p=0.05) and increased uPCR 315 
(OR 1.86 for each additional 100mg/mmol; 95% CI, 1.11 to 3.10; p=0.02) at 316 
conception as independent predictors of poor obstetric outcome (Table 3). 317 
Reduced eGFR (OR 0.98 per mL/min/1.73m2; 95% CI, 0.96 to 0.99; p=0.04), 318 
increased uPCR (OR 1.50 for each additional 100mg/mmol; 95% CI, 1.02 to 319 
2.20; p=0.04) and live versus deceased donor source (OR 0.35; 95% CI, 0.15 320 
to 0.85; p=0.02) were predictors of pregnancy associated transplant 321 
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dysfunction (Table 4). Multivariable analysis did not demonstrate any 322 
independent predictors of either obstetric or kidney outcomes (Tables 3, 4). 323 
 324 
Matched cohort study 325 
Of 93 women with first pregnancy, 83 could be matched to non-pregnant renal 326 
transplant controls. Baseline characteristics of pregnant women and non-327 
pregnant controls are shown in Table 5. There were no significant differences 328 
between pregnant women who were matched and the 10 women who were 329 
not matched. 330 
Transplant function declined in both groups but there were no significant 331 
differences in eGFR between pregnant women and non-pregnant controls at 332 
‘matching day’, 1 year, 5 years or 10 years after the ‘matching day’ (Figure 2). 333 
Acute rejection episodes occurred in 5 pregnant women during the gestational 334 
period and 2 non-pregnant controls during the corresponding time period, 335 
respectively. By Kaplan Meier analysis, overall transplant survival was similar 336 
for pregnant and control subjects (1-year transplant survival 98.8% vs. 98.8%, 337 
5-year 75.9% vs. 81.1%, and 10-year 54.2% vs. 68.5%; p=0.79). Transplant 338 
survival censored for death with functioning kidney was similar for pregnant 339 
and control subjects (1-year death censored transplant survival 98.8% vs. 340 
98.8%, 5-year 79.6% vs. 81.1%, and 10-year 59.8% vs. 69.8%; p=0.60) 341 
(Figure 3A). There was no difference in patient survival between pregnant 342 
women and non-pregnant controls (1-year survival 100% vs. 100%, 5-year 343 
survival 95.5% vs. 100%, 10-year survival 88.1% vs. 98.1%, and 20-year 344 
survival 88.1% vs. 72.0%; p=0.77) (Figure 3B). 345 
  346 
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Discussion 347 
We report on 138 pregnancies in 89 transplant recipients over four decades. 348 
To the best of our knowledge, this is the largest number of pregnancies 349 
reported from a single centre with long-term follow-up and adequate controls 350 
and the first one that uses pre-pregnancy eGFR instead of serum creatinine. 351 
Our data suggest the majority of pregnancies in renal transplant recipients 352 
have a good outcome with live birth occurring in 74% of all pregnancies and 353 
96% of pregnancies reaching 20 weeks gestation. Rates of prematurity (61%), 354 
low birth weight (52%) and preeclampsia (14%) are high. 23% of babies were 355 
small for gestational age. The majority of preterm births were due to medical 356 
intervention (89%) for fetal and maternal complications including fetal growth 357 
restriction, deteriorating kidney function, uncontrolled hypertension and 358 
preeclampsia. The majority of deliveries were by caesarean section (80%), of 359 
which almost half were emergency procedures. Not all caesarean deliveries 360 
were due to medical reasons. In our experience obstetricians have a low 361 
threshold for performing caesarean section in kidney transplant patients, 362 
based on perceived higher risks associated with proceeding to term vaginal 363 
delivery in this population.  364 
The 74% live birth rate is similar to various registry reports(2, 5, 6, 13). Early 365 
pregnancy losses (miscarriages and ectopic pregnancies) were more frequent 366 
in our study (19% vs. 14%(8)).  367 
Live birth rates did not change over four decades. Spontaneous miscarriage 368 
and ectopic pregnancy rates increased from 13% in the 1970’s to 36% after 369 
2000 despite reduction in terminations. This may represent willingness to 370 
support higher risk pregnancies in recent times or prior under-reporting of 371 
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early pregnancy losses. However, the mean eGFR prior to pregnancy did not 372 
decline over the decades. 373 
Renal impairment and proteinuria were associated with poor pregnancy 374 
outcome, as reported previously(3, 14). Historically, pre-pregnancy serum 375 
creatinine of >1.5mg/dL predicts adverse pregnancy outcomes(5, 15, 16). We 376 
used a pre-pregnancy eGFR cut-off of 45ml/min/1.73m2, which corresponds to 377 
serum creatinine of 1.5mg/dL, and we showed that women with CKD stage 3B 378 
or more advanced renal disease are at greater risk for small gestational age 379 
and low birth weight. We found no relationship between deceased and live 380 
donation and pregnancy outcome(3, 17) but live donation was associated with 381 
smaller drops in eGFR and better renal function 1 year after delivery probably 382 
because the women with living kidney donors had better renal function at the 383 
time of pregnancy. Others have reported preexisting hypertension(5), time 384 
from transplantation(2, 7, 8), pre-pregnancy dialysis vintage(18), and number 385 
of previous transplants(3) as predictive of adverse events; however, we did 386 
not observe these relationships. 387 
This is the first study to report on a large number of multiple pregnancies with 388 
the same transplant. Women who had multiple pregnancies had similar 389 
obstetric and long-term kidney outcomes to women who had single 390 
pregnancies. 391 
Perinatal mortality among babies born to transplant recipients was 2.9% 392 
compared to <1% in the general UK and US population and between 1% to 393 
5.8% in women with transplants(2, 3, 19). 394 
Incidence of birth defects in our cohort was similar to the general population of 395 
3–5%. We do not have data on long-term developmental outcomes. 396 
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All neonatal deaths, congenital anomalies and very preterm deliveries 397 
occurred in pregnancies 3 or more years post-transplant. The average age at 398 
time of pregnancy for women with pregnancies ≥3 years post-transplant was 399 
30.2 years. 400 
There were 6 episodes of BPAR during pregnancy compared with 6 episodes 401 
before pregnancy. In the case-cohort study, rejection episodes were more 402 
common in pregnant women compared with non-pregnant controls (5 versus 403 
2) but this did not translate into worse transplant or patient survival. This is 404 
likely the consequence of adjustment of immunosuppression or 405 
pharmacokinetic changes in calcineurin inhibitors during pregnancy which 406 
make interpretation of whole blood trough concentrations particularly 407 
challenging. Sixteen patients returned to dialysis during pregnancy or within 2 408 
years following delivery. 409 
Renal transplant recipients are traditionally counselled to wait two years after 410 
transplantation before conceiving(20). More potent immunosuppressive 411 
strategies have decreased rejection rates at one year post-transplant, whilst 412 
waiting time for deceased donor organs has increased, leaving women fewer 413 
potential childbearing years. In 2005, the American Society of Transplantation 414 
decreed that pregnancy may be considered after 1 year in women at lower 415 
risk(21) based on existing evidence(22, 23). Our data support this approach. 416 
In the case-cohort study there was no significant difference in eGFR at 1, 5 417 
and 10 years after study entry between pregnant women and non-pregnant 418 
controls; mean eGFR fell in both groups, however there was no difference in 419 
transplant survival, death censored transplant survival or patient survival. The 420 
immunosuppression regimens used in both groups were similar but as 421 
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expected more patients in the control group used mycophenolate mofetil. Our 422 
data showed that 90% of mothers survive 20 years from first pregnancy to 423 
raise the child to adulthood.  However at the child’s 10th birthday, there is 424 
approximately 40% chance that the mother’s transplant will have failed. This 425 
is useful information for physicians involved in pre-conception counselling. 426 
We acknowledge this study has limitations. The analysis was retrospective 427 
although data were retrieved mainly from prospectively maintained 428 
comprehensive electronic records. Single centre studies have the advantage 429 
of uniformity of therapeutic approach but treatments, including 430 
immunosuppressive regimens, have changed substantially over this time 431 
period. Therefore we analysed different eras but were unable to detect any 432 
era effect. Single centre studies may lack generalisability but it is reassuring 433 
that our outcomes compare with high-quality national data(2, 4) and a recent 434 
meta-analysis(8). The number of cases available for study was higher than 435 
previous single centre reports but the low rate of serious obstetric 436 
complications means some analyses may be underpowered to detect 437 
important associations. Under-reporting of early pregnancies is likely so we 438 
can be less definitive about incidence of conception and early pregnancy 439 
complications. Diagnostic criteria for renal transplant rejection have changed 440 
over the era of this study, with the introduction of C4d staining and routine 441 
testing for donor specific antibodies occurring only during the last 10 years of 442 
this study. Therefore we cannot definitively exclude a component of antibody-443 
mediated rejection in the patients who had episodes of rejection. 444 
In this large single-centre study of pregnancy and kidney outcomes extending 445 
over 40 years we observe the majority of pregnancies in renal transplant 446 
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recipients to have good outcomes. Rates of live and preterm births have not 447 
changed over this period despite advances in immunosuppression. We 448 
confirm previous reports of high rates of prematurity, low birth weight and 449 
preeclampsia and emphasise the influence of transplant function and 450 
proteinuria on obstetric and renal risks. Compared with appropriately matched 451 
non-pregnant female renal transplant recipients, there were no significant 452 
differences in long-term transplant and patient survival in renal transplant 453 
mothers. This information is reassuring for patients and clinicians when 454 
counselling women with transplants contemplating pregnancy. 455 
 456 
 457 
 458 
 459 
 460 
 461 
 462 
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 464 
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Table 1 575 
Baseline characteristics of study patients 
Age at transplantation (mean [SD]) 25.2 (6.4) 
Age at pregnancy (mean [SD]) 30.3 (5.1) 
Time since transplant (yr; median [IQR]) 3.6 (1.9 – 7.0) 
Cause of ERF 
     Glomerulonephritis (n [%]) 
     Reflux nephropathy (n [%]) 
     Other (n [%]) 
 
32 (36.0) 
43 (48.3) 
14 (15.7) 
Donor source 
     Deceased (n [%]) 
     Live (n [%]) 
 
87 (63.0) 
51 (37.0) 
Previous kidney transplant (n [%]) 30 (21.7) 
Years on RRT (median [IQR]) 6.9 (3.8 – 10.4) 
Treatment for hypertension (n [%]) 56 (40.6) 
     Systolic BP (mmHg; mean [SD]) 126.9 (16.6) 
     Diastolic BP (mmHg; mean [SD]) 80.5 (9.8) 
Pre pregnancy eGFR  (ml/min/1.73m2; mean [SD]) 55 (20.4) 
Post pregnancy eGFRa  (ml/min/1.73m2; mean [SD]) 50 (23.0) 
Pre pregnancy uPCR (mg/mmol; median [IQR]) 15 (10 – 33) 
Post pregnancy uPCRa (mg/mmol; median [IQR]) 30 (10 – 70) 
Pre pregnancy acute rejection (n [%]) 6 (4.3) 
a at six months 
ERF, established renal failure; RRT, renal replacement therapy; BP, blood 
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pressure; eGFR, estimated glomerular filtration rate; uPCR, urine 
protein:creatinine ratio. 
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Table 2 597 
Obstetric outcomes according to pre-pregnancy eGFRa 
 ≤45ml/min/1.73m2 
N=41 
>45ml/min/1.73m2 
N=91 
P 
valueb 
Live birth (n; [%]) 27 (65.9) 71 (78.0) 0.51 
Gestational age (wk; median 
(IQR)) 
34.3 (33.3, 36.7) 36.5 (33.9, 37.9) 0.02 
Birth weight (g; mean [SD]) 2128 (832) 2599 (670) 0.007 
Preeclampsia (n [%])c 7 (25.9) 8 (11.3) 0.08 
a excludes 6 cases with missing data 
b t-test or chi-squared test or Mann-Whitney-U test where appropriate 
c excludes <20wk gestation 
eGFR, estimated glomerular filtration rate; 
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Table 3 609 
Factors associated with composite adverse obstetric outcomea 
Factor Unadjusted OR 
(95% CI) 
P 
Value 
Adjusted OR 
(95% CI) 
P 
Value 
Age at pregnancy  
(each additional year) 
1.04 (0.97-1.12) 0.23 1.20 (0.94-1.50) 0.67 
Time since transplant  
(each additional year) 
1.03 (0.95-1.12) 0.40 1.03 (0.95-1.12) 0.44 
Cause of ERF 
     Glomerulonephritis 
     Reflux nephropathy 
 
1.03 (0.22-4.70) 
3.20 (0.78-13.0) 
 
0.97 
0.11 
 
- 
- 
 
 
 
Pre pregnancy eGFR (each 
additional ml/min/1.73m2) 
0.98 (0.96-1.00) 0.05 0.99 (0.97-1.01) 0.32 
Pre pregnancy uPCR 
(additional 100mg/mmol) 
1.86 (1.11-3.10) 0.02 1.68 (0.98-2.88) 0.06 
Era of transplant  
     1973 to 1980 
     1981 to 1990 
     1991 to 2000 
     2001 to 2013 
 
1.53 (0.40-5.82) 
0.65 (0.22-1.87) 
1.02 (0.36-2.89) 
0.65 (0.17-2.48) 
 
0.53 
0.42 
0.98 
0.53 
 
- 
- 
- 
- 
 
Live vs. Deceased donor 1.09 (0.53-2.26) 0.82 -  
CNI-based IS regime 0.80 (0.37-1.74) 0.57 -  
a first or second trimester loss, stillbirth, neonatal mortality, very preterm birth and 
fetal congenital anomaly 
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ERF, established renal failure; eGFR, estimated glomerular filtration rate; uPCR, 
urine protein:creatinine ratio; CNI, calcineurin inhibitor; IS, immunosuppression. 
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Table 4 631 
Factors associated with pregnancy associated transplant dysfunctiona 
Factor Unadjusted OR  
(95% CI) 
P 
value 
Adjusted OR 
(95% CI) 
P 
value 
Age at pregnancy  
(each additional year) 
0.96 (0.89-1.04) 0.29 0.94 (0.86-1.03) 0.18 
Time since transplant  
(each additional year) 
0.93 (0.84-1.03) 0.15 0.98 (0.96-1.01) 0.14 
Cause of ERF 
     Glomerulonephritis 
     Reflux nephropathy 
 
2.35 (0.44-12.6) 
2.60 (0.51-13.3) 
 
0.32 
0.25 
 
- 
- 
 
Pre pregnancy eGFR (each 
additional ml/min/1.73m2) 
0.98 (0.96-0.99) 0.04 0.98 (0.96-1.01) 0.13 
Pre pregnancy uPCR  
(additional 100mg/mmol) 
1.50 (1.02-2.20) 0.04 1.24 (0.82-1.88) 0.31 
Era of transplant 
     1973 to 1980 
     1981 to 1990 
     1991 to 2000 
     2001 to 2013 
 
0.52 (0.09-3.14) 
1.13 (0.35-3.68) 
1.97 (0.62-6.26) 
1.91 (0.32-11.5) 
 
0.48 
0.84 
0.25 
0.48 
 
- 
- 
- 
- 
 
Live vs. Deceased donor 0.35 (0.15-0.85) 0.02 0.48 (0.18-1.27) 0.17 
CNI-based IS regime  1.85 (0.76-4.50) 0.18 1.24 (0.42-3.72) 0.70 
a ≥20% loss of eGFR between immediately pre-pregnancy and 1 year after delivery 
ERF, established renal failure; eGFR, estimated glomerular filtration rate; uPCR, 
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urine protein:creatinine ratio; CNI, calcineurin inhibitor; IS, immunosuppression. 
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Table 5 653 
Baseline characteristics cases vs. controls 
 Pregnancies 
N=83 
Controls 
N=83 
P 
valuea 
Age at study entry (years; mean [SD]) 29.4 (5.3) 31.1 (5.9) 0.05 
Months since transplant (median [IQR]) 34 (17.5 - 
64.5) 
32 (14.0 – 
59.0) 
0.97 
Glomerulonephritis (n [%]) 34 (41.0) 24 (28.9) 0.1 
Reflux nephropathy (n [%]) 36 (43.4) 33 (39.8) 0.64 
Immunosuppression 
     Cyclosporine (n [%]) 
     Tacrolimus (n [%]) 
     No calcineurin inhibitor (n [%]) 
     Azathioprine (n [%]) 
     Mycophenolate mofetil (n [%]) 
 
53 (63.9) 
17 (20.5) 
13 (15.7) 
55 (66.3) 
0 (0) 
 
52 (62.7) 
17 (20.5) 
14 (16.9) 
43 (51.8) 
16 (19.3) 
 
0.9 
1 
0.8 
0.23 
<0.001 
Systolic BP (mmHg; mean [SD]) 
126.2 (15.4) 
128.3 
(15.3) 
0.4 
Diastolic BP (mmHg; mean [SD]) 80.9 (10.3) 80.6 (8.9) 0.8 
eGFR at matching day (ml/min/1.73m2; 
mean [SD]) 
53.9 (18.2) 53.6 (17.0) 0.9 
uPCR at matching day (mg/mmol; 
median [IQR]) 
15 (10 - 30) 
20 (10 - 
50) 
0.13 
uPCR>100mg/mmol at matching day (n 
[%]) 
10 (12.5)b 9 (11.4)c 0.83 
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Follow-up (yr; median [IQR]) 8.1 (3.8 - 
17.3) 
9.0 (3.8 - 
16.6) 
0.94 
a t-test or chi-squared test or Mann-Whitney-U test where appropriate 
b excludes 3 cases with missing data      
c excludes 4 cases with missing data 
BP, blood pressure; eGFR, estimated glomerular filtration rate; uPCR, urine 
protein:creatinine ratio. 
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Figure 1: Four most common maternal immunosuppression regimens by 671 
decade of transplant. No immunosuppression information was recorded for 672 
2 patients between 1981 and 1990 and 4 patients between 1991 and 2000. 673 
One patient between 1991 and 2000 did not require immunosuppression 674 
(transplant from identical twin). Pred, prednisolone; Aza, azathioprine; CsA, 675 
cyclosporine A; Tac, tacrolimus. 676 
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Figure 2: Estimated mean eGFR and standard deviation in pregnant 687 
women and non-pregnant controls with a transplant kidney. The 688 
difference in eGFR between cases and controls was not statistically 689 
significant at ‘matching day’, 6 months, 1 year, 5 years or 10 years after the 690 
‘matching day’. 691 
eGFR counted as ‘0’ from time of transplant failure and return to dialysis. 692 
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 700 
Figure 3. Kaplan Meier survival estimates in pregnant women and non-pregnant controls with a transplant kidney. (A) 701 
Transplant survival censored for death. (B) Patient survival. 702 
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